|1.||Conde, Diego: 10 articles (02/2015 - 10/2013)|
|2.||Beatch, Gregory N: 9 articles (06/2013 - 12/2004)|
|3.||Torp-Pedersen, Christian: 7 articles (06/2013 - 03/2008)|
|4.||Fedida, David: 7 articles (04/2013 - 11/2005)|
|5.||Camm, A John: 6 articles (02/2014 - 03/2008)|
|6.||Dickinson, Garth: 6 articles (06/2013 - 12/2004)|
|7.||Costabel, Juan Pablo: 5 articles (01/2014 - 10/2013)|
|8.||Lambardi, Florencia: 4 articles (02/2015 - 10/2013)|
|9.||Lip, Gregory Y H: 4 articles (04/2014 - 12/2009)|
|10.||Trivi, Marcelo: 4 articles (01/2014 - 10/2013)|
06/01/2011 - "In pivotal, randomized, phase III trials, intravenous vernakalant 3 mg /kg administered as a 10-minute infusion, followed by a 2 mg/kg 10-minute infusion after 15 minutes if atrial fibrillation persisted, was effective in the rapid termination of recent-onset atrial fibrillation in nonsurgical patients (≥ 3 hours' to ≤ 7 days' duration) and in those with postoperative atrial fibrillation (3-72 hours' duration) following cardiac surgery. "
01/22/2011 - "In pivotal randomized, phase III trials, intravenous vernakalant 3 mg/kg administered as a 10-minute infusion, followed by a 2 mg/kg 10-minute infusion after 15 minutes if atrial fibrillation persisted, was effective in the rapid termination of recent-onset atrial fibrillation in nonsurgical patients (≥3 hours' to ≤7 days' duration) and in those with postoperative atrial fibrillation (3-72 hours' duration) following cardiac surgery. "
03/01/2013 - "At test concentrations encompassing free plasma concentrations associated with clinical efficacy for conversion of atrial fibrillation, vernakalant (1-10 μM) displayed no significant direct effects on human resistance artery tone or ventricular contractility. "
06/01/2011 - "Intravenous vernakalant is effective for the rapid pharmacological conversion of atrial fibrillation. "
04/01/2012 - "Several clinical trials have shown that vernakalant is effective in terminating recent onset atrial fibrillation (AF). "
|2.||Atrial Flutter (Flutter, Atrial)
11/01/2008 - "In clinical Phase II and III studies, vernakalant was moderately (approximately 50%) effective in converting AF of short duration (< 7 days), and effective (approximately 70-80%) in converting AF of less than 72 h, but was not effective in converting long duration AF (>7 days) or atrial flutter. "
12/01/2009 - "Vernakalant seems to be effective in terminating recent-onset AF, but is not efficacious in long-lasting AF and atrial flutter. "
06/01/2012 - "This study examined the safety and efficacy of vernakalant in converting atrial flutter (AFL) to sinus rhythm. "
07/01/2012 - "Plasma vernakalant concentration data from 5 phase 2 and 3 clinical trials of vernakalant in patients with AF or atrial flutter and a phase 1 study in healthy volunteers were used to construct a population pharmacokinetic model. "
06/01/2012 - "Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial."
|3.||Cardiac Arrhythmias (Arrythmia)
06/01/2011 - "Increases in QRS or QT intervals were transient, and there was no increased incidence of ventricular arrhythmia observed with vernakalant compared with placebo. "
01/22/2011 - "Increases in QRS or QT intervals were transient, and there was no increased incidence of ventricular arrhythmia observed with vernakalant compared with placebo. "
11/01/2010 - "The first infusion of placebo or vernakalant (3 mg/kg) was given for 10 minutes followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if the arrhythmia had not terminated. "
11/01/2005 - "RSD1235 is a novel drug recently shown to convert AF rapidly and safely in patients.(1) Its mechanism of action has been investigated in a rat model of ischemic arrhythmia, along with changes in action potential (AP) morphology in isolated rat ventricular myocytes and effects on cloned channels. "
11/01/2010 - "Patients with either AF or atrial flutter were randomized in a 1:1 ratio to receive vernakalant (n = 138) or placebo (n = 138) and were stratified by an arrhythmia duration of >3 hours to ≤7 days (short duration) and 8 to ≤45 days (long duration). "
|4.||Critical Illness (Critically Ill)
01/01/2014 - "Vernakalant converts new-onset AF to sinus rhythm in approximately 50% of patients, but data on its efficacy and safety in critically ill patients are lacking. "
01/01/2014 - "This study investigates the suitability, safety, and efficacy of vernakalant in critically ill patients with new onset atrial fibrillation (AF) after cardiac surgery. "
01/01/2014 - "Suitability, efficacy, and safety of vernakalant for new onset atrial fibrillation in critically ill patients."
10/01/2011 - "The novel Kv1.5 channel blocker vernakalant for successful treatment of new-onset atrial fibrillation in a critically ill abdominal surgical patient."
|5.||Heart Diseases (Heart Disease)
02/01/2015 - "In our study, the absence of any kind of structural heart disease and preserved systolic function were associated with greater conversion rate with vernakalant."
10/01/2011 - "Vernakalant can be applied to hemodynamically stable patients with structural heart disease and represents a novel alternative option for rapid pharmacological cardioversion."
01/01/2015 - "A series of clinical trials have demonstrated the rapid, efficacious and safe effect of vernakalant over placebo or conventional AADs in terminating recent-onset AF among patients with structurally normal or minimal heart disease; but current evidence does not show a superior role of vernakalant in treating long-duration AF or atrial flutter. "
04/01/2014 - "Intravenous vernakalant (Brinavess) has been developed and approved in Europe as a safe and efficacious drug to rapidly convert recent onset atrial fibrillation to sinus rhythm in patients with no minimal or structural heart disease. "
10/30/2013 - "Recently a group published that vernakalant had a 90% conversion rate in patients with recent onset atrial fibrillation without structural heart disease versus 100% conversion rate in the electrical cardioversion group. "
|6.||Ion Channels (Ion Channel)
|1.||Electric Countershock (Cardioversion)
|3.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|5.||Nebulizers and Vaporizers (Inhaler)